In Re: Effexor XR Antitrust Litigation Settlement Documents

This antitrust lawsuit was filed against brand drug manufacturer Wyeth and generic drug manufacturer Teva, alleging that Wyeth and Teva violated federal antitrust laws by delaying the introduction of generic versions of Effexor XR into the United States market via a “pay for delay” or “reverse payment” agreement. Effexor XR is prescribed for the treatment of depression, anxiety, panic attacks, and social anxiety disorder.

The Court has preliminarily approved a settlement agreement for $39 million between Wyeth and a class of persons and entities that purchased brand or generic Effexor XR directly from Wyeth or Teva. Such direct purchasers have rights that may be affected by the settlement. For additional information about the lawsuit, the settlement, the legal rights and options of direct purchasers, and the deadlines by which those options must be exercised, please review the documents attached to this webpage.

The claims against Teva have not yet been settled; those claims are still being litigated.

• ECF 287 – Complaint
• ECF 732 – Preliminary Approval Order
• ECF 729 – DPPs Motion for Preliminary Approval
• ECF 729-1 – Declaration of Peter S. Pearlman ISO Preliminary Approval
• ECF 729-2 – Settlement Agreement
• ECF 729-3 – Proposed Plan of Allocation
• ECF 729-4 – Declaration of Jeffrey J. Leitzinger, Ph.D.
• ECF 729-5 – Declaration of William W. Wickersham of RG2
• ECF 729-6 – Memo ISO DPPs Motion for Preliminary Approval
• D740 – Motion for Attorneys Fees
• D740-1 – Effexor Mem. ISO Mot for Attorneys Fees
• D740-2 – Pearlman Declaration with Exhs
• D740-13 -CPA Signed Declaration
• D740-14 – CERT OF SERVICE